BioSpace News Archive

Sonoma Pharmaceuticals, Inc. today announced the launch of its MicrocynAH animal health care products in the Menards chain of home improvement stores in the United States.

Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, will present an oral presentation at the upcoming International Association of Parkinsonism and Related Disorders XXIX World Congress on Parkinson’s Disease and Related Disorders, taking place in Lisbon, Portugal from May 19-22, 2024.

Vera Therapeutics, Inc. reported its business highlights and financial results for the first quarter ended March 31, 2024.

Disc Medicine, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, reported financial results for the first quarter ended March 31, 2024.

VYNE Therapeutics Inc. announced financial results as of and for the three months ended March 31, 2024 and provided a business update.

RAPT Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.

NewAmsterdam Pharma Company N.V., a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol, for whom existing therapies are not sufficiently effective or well-tolerated, announced corporate updates and financial results for the quarter ended March 31, 2024.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, announced five abstracts on primary biliary cholangitis will be presented at Digestive Disease Week® 2024.

Akoya Biosciences, Inc., The Spatial Biology Company®, and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma patients, announced an exclusive agreement under which the parties will develop market opportunities for combining Akoya’s PhenoImager HT platform and NeraCare’s Immunoprint assay for patient stratification and therapy selection in early-stage melanoma patients.

Movano Health (Nasdaq: MOVE) announced that it successfully submitted updated pivotal clinical trial results as well as proof of enhanced medical device usability on April 22, 2024 to the U.S. Food and Drug Administration (FDA) as part of its 510(k) filing for the Company’s first commercial medical device, the Evie Med Ring pulse oximeter.